Back to search

Article

Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study

2024-07-19

Abstract excerpt

<title>Abstract</title> <p><bold>Introduction</bold>: Venetoclax (VEN) was the only Bcl-2 inhibitor approved by FDA and showed desired efficacy. However, VEN showed large differences in clinical efficacy, which may due to pharmacokinetic variability. <bold>Objectives</bold>:The purpose of the study was to explore the relationships between the plasma concentration and efficacy of VEN, and identify potential influe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cbfa0986-8793-525f-bd64-c3e21e799f53
DOI
10.21203/rs.3.rs-4565192/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective studyDOI 10.21203/rs.3.rs-4565192/v1
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study.Semantic proximity
Association Between Venetoclax Concentration and Febrile Neutropenia in Acute Leukemia: A Retrospective AnalysisSemantic proximity
Association Between Venetoclax Concentration and Febrile Neutropenia in Acute Leukemia: A Retrospective AnalysisSemantic proximity
Clinical Experience With Venetoclax in Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia.Semantic proximity
Real-life Multicenter Experience of Long-term Treatment With Venetoclax Plus Azacitidine for Acute Myeloid Leukemia in ChinaSemantic proximity
Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center studySemantic proximity
The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.Semantic proximity
Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China.Semantic proximity
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.Semantic proximity
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemiaSemantic proximity
Venetoclax combined with hypomethylating agents and the CAG regimen (DCAG) in relapsed/refractory AML: A single- center clinical trialSemantic proximity
Effect of oral posaconazole on venetoclax plasma concentration and efficacy in patients with acute myeloid leukemiaSemantic proximity
Select a neighboring publication to make it the new centre.